REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
03/09/2026
Back to search
Official data from USPTO
CINCLUS PHARMA
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
22
Latest update
03/10/2026
Trademark type
Combined
Nice classes
5, 42, 44
Filing date
05/20/2020
Registration date
03/09/2021
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
03/09/2021
Last transaction
03/10/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
5
Owner type
64
Owner location
CH
Examiner
SALCIDO, JOHN CHARLES
Law office
N40
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the stylized wording "CINCLUS PHARMA" where the wording "CINCLUS" is in black and the dot on the letter "I" is in green color; and the wording "PHARMA" is in green color".
Holders and representatives
Holders
Cinclus Pharma AG
Representatives
Charles P. Guarino Moser Taboada
Technical classification
Nice Classes
Class 5Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations and substances for the treatment of gastrointestinal diseases and disorders; Medicinal preparations and substances for gastrointestinal diseases and disorders; Pharmaceuticals for the treatment of gastrointestinal diseases and disorders; Pharmaceutical preparations for treating gastrointestinal diseases and disorders; Medicines for the treatment of gastrointestinal diseases and disorders
Class 42
Development of pharmaceutical preparations and medicines; pharmaceutical drug development services; scientific research in the field of pharmacy; scientific research and development; pharmaceutical products development; medical research
Class 44
Medical services; Healthcare advisory services in the field of medical treatmentwellnessnutrition; Pharmaceutical advice; Advisory services relating to pharmaceuticalsnamely pharmaceutical advicemedical and pharmaceutical consultation; Medical counseling
Publications
History of USPTO decisions and trademark events.
22 publications found
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
07/05/2021
FICS
FINAL DISPOSITION NOTICE SENT TO IB
06/16/2021
FIMP
FINAL DISPOSITION PROCESSED
06/16/2021
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
06/09/2021
R.PR
REGISTERED-PRINCIPAL REGISTER
03/09/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
12/22/2020
PUBO
PUBLISHED FOR OPPOSITION
12/22/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
12/02/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
11/16/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
11/16/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
11/16/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
11/16/2020
RFNT
REFUSAL PROCESSED BY IB
10/03/2020
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
09/14/2020
RFRR
REFUSAL PROCESSED BY MPU
09/14/2020
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
08/20/2020
CNRT
NON-FINAL ACTION WRITTEN
08/19/2020
DOCK
ASSIGNED TO EXAMINER
08/18/2020
MAFR
APPLICATION FILING RECEIPT MAILED
07/10/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
07/06/2020
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
07/02/2020
Continuous trademark protection
Get notified about every new filing that threatens CINCLUS PHARMA or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.